India Restricts Cold Medicines for Children Under Four Over Safety Concerns
核心洞察
India's Ministry of Health and Family Welfare has restricted the manufacture, sale, and distribution of fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four years of age.
The restriction, issued under Section 26A of the Drugs and Cosmetics Act, 1940, requires a prominent warning on labels, package inserts, and promotional materials stating the combination must not be used in children below four.
The decision follows recommendations from an Expert Committee and the Drugs Technical Advisory Board, which found safer alternatives exist and the combination may pose risks such as excessive drowsiness, agitation, and rapid heartbeat.
India's Ministry of Health and Family Welfare has restricted the manufacture, sale, and distribution of all fixed-dose combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride for use in children below four years of age. The directive, issued under Section 26A of the Drugs and Cosmetics Act, 1940, came into force upon publication in the Official Gazette and follows recommendations from an Expert Committee constituted by the Health Ministry and the Drugs Technical Advisory Board (DTAB).
The regulatory action requires manufacturers to carry a prominent warning on the drug label, package insert, and promotional material stating: "Fixed Dose Combination shall not be used in children below four years of age." The government has indicated that these combinations may pose risks to children below four and that safer alternatives are available.
Clinical Rationale and Safety Concerns
Dr Rommel Tickoo, senior director of internal medicine at Max Hospital, explained the clinical basis for the restriction: "In children below four years, combination cold medicines containing chlorpheniramine and phenylephrine can cause excessive drowsiness or agitation, rapid heartbeat and, in some cases, serious adverse effects. Since these medicines offer limited benefit for a common cold, parents should prefer safer measures such as saline nasal drops, adequate fluids and honey for children above one year."
The move represents the latest step in a regulatory review that dates back to 2023, when concerns were first raised over the use of the combination in young children. The issue was re-examined in 2024 with paediatricians, with DTAB recommending that the warning apply to all formulations.
Regulatory Timeline and Scope
The Centre initially imposed restrictions in April 2025, and DTAB revisited the matter in February 2026, agreeing to extend the restriction to all formulations. At its February 16, 2026 meeting, DTAB agreed that the formulations should not be used in children below four. The latest notification now covers all such formulations, including those manufactured or imported and marketed in India.
Industry Impact and Compliance
For pharmaceutical companies, the regulatory framework requires careful portfolio and operational management. Manufacturers of popular pediatric cold and cough syrups, such as Glenmark Pharmaceuticals, Alembic Pharmaceuticals, and Haleon, have had to adapt to these safety standards.
A significant aspect of the regulation is the clarification from the Delhi High Court, which ruled that the ban is not retrospective. This means existing stocks manufactured before the notification date could continue to be sold, helping companies manage inventory levels and reduce potential financial losses from the disposal of non-compliant stock. However, companies continue to face operational costs associated with updating manufacturing lines, labeling, and product documentation to ensure full compliance with the new safety norms.
The financial impact for manufacturers includes the cost of compliance and the need to pivot marketing strategies toward products that align with the latest safety recommendations from the Drugs Technical Advisory Board. The long-term monitorable for shareholders remains the company's ability to maintain revenue growth despite these regulatory product changes and the potential for similar regulatory action on other FDC categories in the future.